Cat. #162442
Anti-CAR Whitlow Peptide Linker Clone 1G2G2
Cat. #: 162442
Sub-type: Primary antibody
Unit size: 1 mg
Target: Chimeric antigen receptor Whitlow scFv peptide linker
Class: Monoclonal
Application: Flow cytometry, IHC
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Erik Kimble, Jocelyn Wright
Institute: Fred Hutchinson Cancer Center
Primary Citation: Kimble et al. 2025. J Immunother Cancer. 2025 Nov 18;13(11):e013123. PMID: 41253496
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CAR Whitlow Peptide Linker Clone 1G2G2
- Tool type ecom: Antibody
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Host: Mouse
- Application: Flow cytometry, IHC
- Description: The anti-CAR Whitlow linker peptide 1G2G2 clone has been developed to detect cells expressing Whitlow linker-containing CARs with different antigen specificities, including those harbouring the widely employed anti-CD19 FMC63-derived scFv as well as other scFvs, such as those targeting B-cell maturation antigen (BCMA) or CD33. Although it has been demonstrated to bind CAR-engineered T cells expressing the Whitlow peptide using FACS analysis, 1G2G2 showed no reactivity to FMC63-Whitlow scFv protein and the Whitlow peptide in binding kinetic studies using recombinant proteins.
- Immunogen: Synthetic Whitlow peptide
- Isotype: IgG2a
Target Details
- Target: Chimeric antigen receptor Whitlow scFv peptide linker
- Target background: While CAR T-cell therapies have revolutionized the treatment of B-lineage malignancies, high-resolution tracking of CAR-engineered cells within the tumor microenvironment (TME) remains a significant technical challenge, particularly in archival formalin-fixed paraffin-embedded (FFPE) tissues. To address this, murine monoclonal antibodies (mAbs) have been developed to specifically target the Whitlow linker, a synthetic peptide commonly utilized in the scFv domains of multiple FDA-approved CAR products (e.g., axi-cel, liso-cel). Because this linker is absent in native human tissue and conserved across various antigen specificities, these mAbs provide a universal tool for the in situ identification, selection, and functional analysis of CAR-expressing cells. This methodology enables a more precise evaluation of CAR T-cell infiltration, persistence, and correlation with clinical outcomes or toxicities.
Applications
- Application: Flow cytometry, IHC
Handling
- Unit size: 1 mg
References
- Kimble et al. 2025.J Immunother Cancer. 2025 Nov 1813(11):e013123. PMID: 41253496
